Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Total Non-Current Liabilities (2018 - 2025)

Regenxbio (RGNX) has 8 years of Total Non-Current Liabilities data on record, last reported at $349.7 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 72.5% year-over-year to $349.7 million; the TTM value through Dec 2025 reached $349.7 million, up 72.5%, while the annual FY2025 figure was $349.7 million, 72.5% up from the prior year.
  • Total Non-Current Liabilities reached $349.7 million in Q4 2025 per RGNX's latest filing, down from $363.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $366.7 million in Q2 2025 and bottomed at $163.2 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $226.7 million, with a median of $205.5 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 278.59% in 2021, then tumbled 33.45% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $178.3 million in 2021, then grew by 0.68% to $179.5 million in 2022, then increased by 21.88% to $218.7 million in 2023, then dropped by 7.33% to $202.7 million in 2024, then surged by 72.5% to $349.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $349.7 million in Q4 2025, $363.1 million in Q3 2025, and $366.7 million in Q2 2025.